• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰岛素瘤患者功能性生长抑素受体的术前检测

Preoperative detection of functional somatostatin receptors in a patient with an insulinoma.

作者信息

Oguni Kohei, Fukushima Shinnosuke, Yamamoto Yukichika, Hasegawa Kou, Hagiya Hideharu, Inoshita Naoko, Otsuka Fumio

机构信息

Department of General Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.

Department of Pathology Moriyama Memorial Hospital Tokyo Japan.

出版信息

Clin Case Rep. 2023 Aug 2;11(8):e7771. doi: 10.1002/ccr3.7771. eCollection 2023 Aug.

DOI:10.1002/ccr3.7771
PMID:37546161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10397476/
Abstract

Octreotide is used in patients with insulinomas to treat hypoglycemia, and somatostatin receptor (SSTR) 2 expression is important for its efficacy. We report a case of insulinoma in a 50-year-old woman that responded to an octreotide test, showed accumulation in somatostatin scintigraphy, and was positive for SSTR2A on immunostaining.

摘要

奥曲肽用于胰岛素瘤患者治疗低血糖，生长抑素受体（SSTR）2的表达对其疗效至关重要。我们报告一例50岁女性胰岛素瘤病例，该病例对奥曲肽试验有反应，在生长抑素闪烁扫描中显示有积聚，免疫染色显示SSTR2A呈阳性。

相似文献

1
Preoperative detection of functional somatostatin receptors in a patient with an insulinoma.胰岛素瘤患者功能性生长抑素受体的术前检测
Clin Case Rep. 2023 Aug 2;11(8):e7771. doi: 10.1002/ccr3.7771. eCollection 2023 Aug.
2
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.奥曲肽治疗胰岛素瘤患者：对低血糖的疗效、与奥曲肽扫描闪烁显像的关系以及抗sst2A和抗sst5抗体免疫染色情况
Eur J Endocrinol. 2005 May;152(5):757-67. doi: 10.1530/eje.1.01901.
3
Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2.一名40岁患有对2型生长抑素受体呈阳性的恶性胰岛素瘤的女性，在接受生长抑素类似物治疗后实现了完全临床缓解且肝转移灶消失。
Horm Res. 2006;65(3):120-5. doi: 10.1159/000091408. Epub 2006 Feb 9.
4
Diagnostic usefulness of radiolabeled pentetreotide scintigraphy and therapeutic efficiency of octreotide in a case of insulinoma.放射性标记的喷替肽闪烁扫描术对胰岛素瘤的诊断价值及奥曲肽的治疗效果
Acta Clin Belg. 1994;49(6):296-301. doi: 10.1080/17843286.1994.11718406.
5
In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.犬胰岛素瘤中功能性生长抑素受体的体外和体内检测
J Nucl Med. 1997 Jul;38(7):1036-42.
6
Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.奥曲肽试验对日本胰岛素瘤患者预测生长抑素受体2表达情况的有效性
Endocr J. 2016;63(2):135-42. doi: 10.1507/endocrj.EJ15-0371. Epub 2015 Nov 14.
7
Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.使用放射性标记的生长抑素类似物、123I-酪氨酰3-奥曲肽和111In-喷曲肽对神经内分泌肿瘤和胰岛素瘤进行定位
Clin Endocrinol (Oxf). 1993 May;38(5):501-6. doi: 10.1111/j.1365-2265.1993.tb00346.x.
8
Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas.针对恶性胰岛素瘤导致的严重低血糖，使用生长抑素类似物和肝转移化疗栓塞治疗。
J Endocrinol Invest. 2011 Oct;34(9):e253-8. doi: 10.3275/7762. Epub 2011 May 27.
9
[Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Experience of 54 cases].[内镜超声检查和生长抑素受体闪烁扫描术在胰岛素瘤和胃泌素瘤术前定位中的价值。54例经验]
Gastroenterol Clin Biol. 2002 Apr;26(4):360-6.
10
A case of malignant insulinoma responsive to somatostatin analogs treatment.一例对生长抑素类似物治疗有反应的恶性胰岛素瘤病例。
BMC Endocr Disord. 2018 Dec 27;18(1):98. doi: 10.1186/s12902-018-0325-4.

本文引用的文献

1
Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.用于治疗高胰岛素血症性低血糖症的生长抑素类似物。
Ther Adv Endocrinol Metab. 2020 Dec 2;11:2042018820965068. doi: 10.1177/2042018820965068. eCollection 2020.
2
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.神经内分泌肿瘤的治疗学：当前方法和未来挑战概述。
Rev Endocr Metab Disord. 2021 Sep;22(3):581-594. doi: 10.1007/s11154-020-09552-x.
3
Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas.
奥曲肽试验对日本胰岛素瘤患者预测生长抑素受体2表达情况的有效性
Endocr J. 2016;63(2):135-42. doi: 10.1507/endocrj.EJ15-0371. Epub 2015 Nov 14.
4
Diagnosis and management of insulinoma.胰岛素瘤的诊断与治疗。
World J Gastroenterol. 2013 Feb 14;19(6):829-37. doi: 10.3748/wjg.v19.i6.829.
5
Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets.生长抑素受体亚型对胰岛素和胰高血糖素分泌的特异性调节作用的表征：对分离的人胰岛的体外研究
J Clin Endocrinol Metab. 2007 Feb;92(2):673-80. doi: 10.1210/jc.2006-1578. Epub 2006 Nov 14.
6
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.奥曲肽治疗胰岛素瘤患者：对低血糖的疗效、与奥曲肽扫描闪烁显像的关系以及抗sst2A和抗sst5抗体免疫染色情况
Eur J Endocrinol. 2005 May;152(5):757-67. doi: 10.1530/eje.1.01901.
7
Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.生长抑素受体2和5是胰岛素瘤中的主要生长抑素受体：一项体内和体外研究。
J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60. doi: 10.1210/jc.2002-021895.
8
111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging.
J Nucl Med. 2000 Mar;41(3):459-62.
9
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.人胎儿垂体培养物中生长抑素受体亚型的特异性。SSTR2和SSTR5在生长激素、促甲状腺激素及催乳素调节中的不同作用。
J Clin Invest. 1997 Feb 15;99(4):789-98. doi: 10.1172/JCI119225.
10
Octreotide.奥曲肽
N Engl J Med. 1996 Jan 25;334(4):246-54. doi: 10.1056/NEJM199601253340408.